1550nm Erbium Laser Treatment Protocol And Safety Guidelines
Dec 15, 2025
The 1550nm Erbium Laser is a non-ablative fractional laser widely used in dermatology and aesthetic medicine. Proper operation and post-treatment management are essential to ensure clinical efficacy while minimizing adverse reactions. This article provides a comprehensive overview of the treatment mechanism, indications, standard operating procedures, safety considerations, and post-treatment care.
1. Treatment Principle and Indications
The 1550nm Erbium laser is a non-ablative fractional laser whose energy is selectively absorbed by water in the dermal layer. This interaction creates controlled Microthermal Treatment Zones (MTZs) with penetration depths of up to 2 mm.
These microthermal injuries stimulate fibroblast activation, promote Type I and Type III collagen remodeling, and enhance elastic fiber regeneration. Through a natural injury–repair–regeneration cycle, the skin achieves gradual structural improvement without epidermal ablation.
Clinical Indications
- Skin rejuvenation: enlarged pores, mild skin laxity, fine lines
- Pigment-related conditions: melasma, post-inflammatory hyperpigmentation (PIH), pigmented dark circles
- Stretch marks: pregnancy-related or expansion-related striae (white or reddish-purple)
- Atrophic acne scars: collagen rearrangement within scar tissue to improve surface depression
2. Standard Operating Procedure
2.1 Pre-Treatment Preparation
Patient Assessment
- Contraindication screening:
- Active herpes infection
- Skin infections
- Keloid-prone skin
- Pregnancy
- History of photosensitizing drugs (e.g., isotretinoin)
- Skin type evaluation (Fitzpatrick scale):
- Higher skin types require reduced energy to minimize post-inflammatory pigmentation.
-
Pretreatment Steps
- Cleanse the treatment area thoroughly.
- Apply compound lidocaine cream under occlusion for 30–40 minutes to reduce discomfort.
- Take standardized clinical photographs and mark high-risk areas (e.g., zygomatic prominences).
2.2 In-Treatment Operation
Device Parameters
- Wavelength: 1550nm (Erbium glass / doped fiber)
- Fractional density: 0.7–1.0
- Higher density for scars
- Lower density for skin rejuvenation
- Scan passes: 2–4 passes per treatment area
Absolute Contraindicated Areas
- Upper eyelid mucosa
- Areola
- Genital mucosa
Recommended Parameters by Treatment Area
| Area | Energy | Spot Size | Passes | Key Notes |
|---|---|---|---|---|
| Periorbital | 2–3 W | 10 mm | 2 | Keep ≥1 mm from eyelid |
| Cheeks (rejuvenation) | 4–7 W | 20 mm | 3 | Reduce energy by 20% over zygoma |
| Forehead / Nasolabial folds | 7–10 W | 15 mm | 3 | Scan perpendicular to wrinkle direction |
| Nose | 5–8 W | 10 mm | 3 | Eye protection mandatory |
| Neck | 3–4 W | 20 mm | 2 | Vertical scanning |
| Acne scars | 9–12 W | 20 mm | 3–4 | Smaller spot + reinforced pass on depressions |
| Stretch marks | 9–12 W | 20 mm | 3 | Scan along the long axis, avoid navel |
2.3 Treatment Technique
- Keep the handpiece perpendicular and in full contact with the skin.
- Maintain 10% spot overlap:
- Excess overlap → thermal injury
- Insufficient overlap → untreated gaps
- Fixed-point or sliding techniques are acceptable.
- Beginners are advised to use fixed-point mode.
Movement speed: 1–2 cm/s
- Too slow → burn risk
- Too fast → insufficient effect
Clinical Endpoints
- Uniform erythema
- Mild edema or wheal-like swelling
- Typically resolves within 1–3 days
Activate cooling systems (cold air or contact cooling) simultaneously to reduce thermal accumulation.
Warning Signs (Immediate Adjustment Required)
- Gray-white discoloration → epidermal necrosis
- Purpura → vascular injury
- Blistering → excessive energy
Adjustments:
- Darker skin types: reduce energy and decrease one pass
- Sensitive skin / rosacea: energy ≤3 W + cold air assistance
2.4 Adverse Reaction Management
| Adverse Reaction | Management |
|---|---|
| Blisters | Sterile drainage + mupirocin + burn ointment + hydrocolloid dressing |
| Persistent erythema | 595nm pulsed dye laser + tacrolimus ointment |
| Hyperpigmentation | Hydroquinone + low-energy large-spot Q-switched 1064nm |
3. Post-Treatment Care Protocol
3.1 Immediate Care (0–24 Hours)
- Cooling and anti-inflammatory care:
Apply refrigerated medical collagen masks for 30 minutes.
- Barrier repair:
Use gels containing EGF or bFGF to promote epithelial regeneration.
3.2 Recovery Phase (1–7 Days)
Cleansing
- Clean with normal saline or sterile distilled water only.
- Avoid cleansers and makeup removers.
Infection Prevention and Hydration
- Antibiotic ointments are generally unnecessary for non-ablative treatments.
- If exudation occurs: apply mupirocin thinly twice daily.
- Use medical-grade moisturizing dressings (e.g., recombinant collagen) daily.
Sun Protection
- Prioritize physical sun protection: wide-brim hats, UV masks, sunglasses.
- Sunscreen: SPF 30+ / PA+++ or higher, reapply every 2 hours
Recommended amount: ≥1 g for full face
3.3 Long-Term Maintenance (1–6 Months)
- Begin tyrosinase inhibitors after 1 month:
- 0.3% arbutin
- 15% vitamin C derivatives
- Hydroquinone
- Tranexamic acid (topical)
- Avoid high-heat environments (saunas, intense exercise) for at least 1 week.
- Avoid photosensitizing foods (celery, coriander) and medications (tetracyclines).
Efficacy Enhancement Strategies
- Acne scars: 1550nm laser + microneedle RF
- Refractory melasma: 1550nm laser + oral tranexamic acid
- Recommended dose: 250 mg, twice daily (under medical supervision)
4. Treatment Interval Recommendation
- Minimum interval between sessions: 4 weeks
- Recommended schedule: every 4–6 weeks
- A full course typically includes 2–4 sessions, adjusted according to skin condition and treatment goals.
The information provided in this article is intended for professional reference in the field of medical aesthetics only and does not constitute medical diagnosis or individualized treatment advice. The 1550nm Erbium laser treatment should be performed by qualified medical professionals, with treatment parameters adjusted based on the patient's skin condition, medical history, and risk assessment. Specific treatment protocols and medication use should follow clinical judgment and comply with local medical regulations. The manufacturer assumes no responsibility for adverse outcomes resulting from improper operation or failure to follow standardized procedures.
